- Report
- August 2023
- 51 Pages
Brazil
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
Italy
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
China
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
Spain
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
Israel
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
Colombia
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
Saudi Arabia
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
South Africa
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
Germany
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
France
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
United Kingdom
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
Turkey
From €533EUR$600USD£465GBP
- Report
- August 2023
- 51 Pages
Canada
From €533EUR$600USD£465GBP
- Report
- October 2024
- 86 Pages
Global
From €3500EUR$4,223USD£3,163GBP

Alpha Glucosidase Inhibitors are a class of drugs used to treat Endocrine and Metabolic Disorders. These drugs work by inhibiting the enzyme alpha-glucosidase, which is responsible for breaking down carbohydrates in the small intestine. This helps to reduce the amount of glucose absorbed into the bloodstream, which can help to control blood sugar levels. Alpha Glucosidase Inhibitors are commonly used to treat type 2 diabetes, as well as other conditions such as polycystic ovary syndrome and gestational diabetes.
Alpha Glucosidase Inhibitors are available in both oral and injectable forms. Common side effects of these drugs include abdominal pain, nausea, and diarrhea. Long-term use of these drugs can also lead to an increased risk of hypoglycemia.
Some companies that produce Alpha Glucosidase Inhibitors include Novo Nordisk, Sanofi, Eli Lilly, and Merck. Show Less Read more